New Delhi: With the onset of monsoon, a varied range of infections and viruses see an uptick in the environment, such as dengue, malaria and Zika virus. In recent years, the Zika virus has gained huge attention across the globe due to its potential to pose a serious threat to health issues particularly affecting pregnant women and their unborn children. To fight this and manage the situation, the Indian Council of Medical Research (ICMR) on Saturday announced the formalisation of a memorandum of agreements (MoS) with various sponsors to advance first-in-human Phase 1 trials for four promising molecules.
What is a First-in-human trial drug?
As per reports, this is the first-in-human kind of clinical trial in which the researchers tested the new drug in humans for the first time. The first-in-human studies are conducted after the new treatment has been tested in laboratory and animal studies and are generally done as Phase 1 clinical trials. For the clinical trials of this study Phase 1, the ICMR is going to partner with a Hyderabad-based Indian Immunologicals to produce a vaccine against Zika virus, a mosquito-borne viral infection. Reports also say that it will also coordinate with Mynvax which is based in Bengaluru for a trial of a vaccine against such season-based infections and flu.
Not only this, but the research body will also do a collaborative study over a small molecule for checking multiple myeloma- a type of blood cancer that majorly affects the plasma cells. This will be done at the Bengaluru-based Aurigene Oncology. Moreover, the apex research body has also signed a pact with Navi Mumbai-based ImmunoACT to conduct a CAR-T cell Therapy advancement study.
According to the official statements of ICMR, this network is designed in such a way that it may help boost India’s capacity to conduct the early-phase clinical trials supported by the robust infrastructure and dedicated people at each trial site and this will look after the effectiveness of the operation.
The Indian Council of Medical Research (ICMR) on Saturday announced the formalisation of a memorandum of agreements (MoS) with various sponsors to advance first-in-human Phase 1 trials for four promising molecules. Health Conditions Health News: Latest News from Health Care, Mental Health, Weight Loss, Disease, Nutrition, Healthcare
